Arvinas to Present at Jefferies Global Healthcare Conference
Rhea-AI Summary
Arvinas (Nasdaq: ARVN), a clinical-stage biotech focused on targeted protein degradation, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, at 9:55 a.m. ET. A live audio webcast will be accessible via the company’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – ARVN
In the Jun 1 session, ARVN declined 4.45%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 18 | CSR / community | Neutral | -3.3% | Company-wide Impact Day highlighting employee volunteer service initiatives. |
| May 12 | Earnings & update | Positive | -0.9% | Q1 2026 results with FDA approval highlight and cash runway into 2H 2028. |
| May 12 | Licensing deal | Positive | -0.9% | Global license granting Rigel exclusive rights to commercialize VEPPANU. |
| May 05 | Earnings date set | Neutral | -1.6% | Announcement of Q1 2026 results date and webcast details. |
| May 01 | FDA approval | Positive | +6.2% | FDA approval of VEPPANU for ESR1‑mutated ER+/HER2‑ advanced breast cancer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news—including FDA approval and a major licensing deal—often saw muted or negative next-day reactions, with the FDA approval being a notable positive outlier.
Over the last month, Arvinas has reported several key milestones. On May 1, the company received FDA approval for VEPPANU, the first FDA‑approved PROTAC, with a 6.16% next‑day gain. Subsequent events on May 12, including Q1 2026 results and a substantial global licensing deal with Rigel, were followed by a modest share decline of about 0.93%. More routine items—like the Q1 earnings date announcement and a company-wide Impact Day—also coincided with small pullbacks, suggesting limited upside reactions to non‑transformational news.
Key Terms
targeted protein degradation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.
A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer Inc., developed the first-and-only U.S. Food and Drug Administration (FDA) approved PROTAC, a type of heterobifunctional protein degrader, VEPPANU™ (vepdegestrant), for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Arvinas and Pfizer have entered into a transaction with Rigel Pharmaceuticals, Inc. for the exclusive global rights of VEPPANU; closing of the transaction is subject to the parties’ receipt of any necessary consents or approvals, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for the treatment of Spinal-Bulbar Muscular Atrophy, also known as Kennedy’s disease; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
VEPPANU is a trademark of Arvinas Operations, Inc.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Alyssa Kuciunas
+1 (331) 481-3751
Alyssa.Kuciunas-c@arvinas.com
